Aurinia lifts 2026 revenue outlook and reports Q3 growth
Aurinia Pharmaceuticals announced third‑quarter 2026 results, showing total revenue of $83.7 million and net income of $31.7 million. The company increased its full‑year 2026 revenue guidance to a range of $325 million‑$330 million and narrowed the net product‑sales outlook to $310 million‑$315 million. It also launched a Phase 4 PRESERVE study for LUPKYNIS and began development of the aritinercept program.
Why it matters
The higher revenue guidance expands the top‑line outlook for investors, while the share repurchase activity noted in the filing indicates continued capital return. The new clinical studies could drive future sales growth for LUPKYNIS.
Key facts
- 1Third‑quarter total revenue was $83.7 million, a 14% increase versus the same quarter in 2025. sec.gov
- 2Net income for the quarter was $31.7 million, essentially flat compared with $31.6 million a year earlier. sec.gov
- 3Diluted earnings per share for the quarter were $0.23. sec.gov
- 4Cash, cash equivalents, restricted cash and investments totaled $486.9 million as of September 30, 2026. sec.gov
- 5Full‑year 2026 total‑revenue guidance was raised to $325 million‑$330 million. sec.gov
- 6Net product‑sales guidance for 2026 was narrowed to $310 million‑$315 million. sec.gov
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.